Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.58 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | F10 | P00742 | 4/20 | 0.54 |
| ▸ | PLAU | P00749 | 4/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.54 |
| ▸ | PLG | P00747 | 3/20 | 0.54 |
| ▸ | PLAT | P00750 | 3/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 8/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248424 | 0.81 | DGAT1 (0.67) | DGAT1CHEK2 | |
| Hydrochloric Acid SCHEMBL1249302 | 0.80 | DGAT1 (0.65) | DGAT1F2F10PLAUPRSS1 | |
| SCHEMBL1252157 | 0.80 | DGAT1 (0.71) | DGAT1F2F10PLAUPRSS1 | |
| SCHEMBL28028783 | 0.79 | CHEK2 (0.60) | PLAUPRSS1CHEK2CYP3A4HDAC1 | |
| SCHEMBL1251957 | 0.78 | DGAT1 (0.60) | DGAT1F2F10PLAUPRSS1 | |
| SCHEMBL1250479 | 0.77 | GAA (0.65) | DGAT1CHEK2CYP3A4 | |
| SCHEMBL1251886 | 0.77 | DGAT1 (0.65) | DGAT1CHEK2 | |
| SCHEMBL4011603 | 0.76 | DGAT1 (0.57) | DGAT1CHEK2CYP3A4 | |
| SCHEMBL20550627 | 0.75 | ALOX5 (0.64) | F2F10PLAUPRSS1PLG | |
| SCHEMBL1252757 | 0.75 | DGAT1 (0.79) | DGAT1CHEK2CYP3A4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077277-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885F2 4352/4885F10 4102/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885F2 4352/4885F10 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.